論文

国際誌
2021年4月1日

Sulfadiazine Hypersensitivity and Desensitization in Children With Congenital Toxoplasmosis: A Report on Two Cases.

The Pediatric infectious disease journal
  • Kei Yamamoto
  • ,
  • Satoshi Kutsuna
  • ,
  • Yasuyuki Kato
  • ,
  • Keiji Goishi
  • ,
  • Hiroyuki Shichino
  • ,
  • Norio Ohmagari

40
4
開始ページ
324
終了ページ
326
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1097/INF.0000000000002972

Combination therapy for toxoplasmosis consists of sulfadiazine, pyrimethamine and leucovorin. Although sulfadiazine can cause hypersensitivity reactions, such as fever, rash and liver dysfunction, there is no consensus on an effective therapy for congenital toxoplasmosis (CTox) without sulfadiazine. We attempted desensitization to sulfadiazine in 2 patients with CTox and sulfadiazine hypersensitivity. Desensitization was achieved for 1 patient.

リンク情報
DOI
https://doi.org/10.1097/INF.0000000000002972
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33181786
ID情報
  • DOI : 10.1097/INF.0000000000002972
  • PubMed ID : 33181786

エクスポート
BibTeX RIS